Albendazole 20 mg/mL Oral Suspension

Albendazole 20 mg/mL Oral Suspension is a compounded liquid medication in which albendazole is uniformly dispersed throughout a liquid medium, creating a homogeneous mixture for accurate administration.

This oral suspension is particularly beneficial for patients who have difficulty swallowing tablets or require precise dosing adjustments. The liquid form allows for flexible dosing regimens tailored to individual patient needs, enhancing compliance and therapeutic outcomes.

Albendazole works by inhibiting the synthesis of microtubules in parasitic worms, leading to impaired glucose uptake and depletion of energy stores, which ultimately causes parasite death. It is commonly used to treat various parasitic infections, including but not limited to ascariasis, hookworm infections, neurocysticercosis caused by Taenia solium (pork tapeworm), and echinococcosis (hydatid disease) caused by Echinococcus granulosus and Echinococcus multilocularis.

For prescribers, the 20 mg/mL concentration provides the flexibility to adjust doses based on the severity

Albendazole 20 mg/mL Oral Suspension is a liquid dosage form in which albendazole, an antiparasitic agent, is uniformly dispersed throughout a liquid medium, providing a homogeneous mixture for administration. This formulation is primarily used to treat a variety of parasitic infections, including neurocysticercosis caused by Taenia solium (pork tapeworm) and hydatid disease caused by Echinococcus granulosus. It works by inhibiting the polymerization of tubulin into microtubules, which is essential for the cellular structure and function of parasites, ultimately leading to their death.

When considering the use of Albendazole 20 mg/mL Oral Suspension, it is crucial to be aware of potential drug interactions that may affect the efficacy and safety of the treatment. Albendazole is metabolized in the liver, primarily by the cytochrome P450 enzyme CYP3A4. Therefore, drugs that induce or inhibit this enzyme can alter the plasma concentration of albendazole, potentially impacting its therapeutic effect and safety profile.

Co-administration with CYP3A4 inducers, such as rifampin, phenytoin, or carbamazepine, may decrease the plasma concentration of albendazole, potentially reducing its efficacy. Patients taking these medications may require dose adjustments or close monitoring to ensure adequate therapeutic levels of albendazole are maintained. Conversely, CYP3A4 inhibitors, such as ketoconazole, itraconazole, or grapefruit juice, may increase the plasma concentration of albendazole, raising the risk of adverse effects. In such cases, careful monitoring and possible dose adjustments are recommended to avoid toxicity.

Albendazole may also interact with other medications that affect liver function or are hepatotoxic. Caution is advised when using albendazole in conjunction with drugs such as valproic acid, which can increase the risk of liver damage. Regular liver function tests are recommended to monitor for potential hepatotoxicity, especially in long-term use or in patients with pre-existing liver conditions.

Additionally, albendazole may interact with medications that affect the bone marrow, such as clozapine or other myelosuppressive agents. Since albendazole can cause bone marrow suppression, concurrent use with these drugs may increase the risk of hematologic toxicity. Monitoring of blood counts is advised to detect any potential adverse effects on the bone marrow.

Patients and prescribers should also be aware of the potential interaction between albendazole and antacids or proton pump inhibitors, which can alter the absorption of albendazole. It is generally recommended to administer albendazole with food to enhance its absorption and efficacy.

As with any medication, it is essential to consider the patient's overall medication regimen and health status when prescribing Albendazole 20 mg/mL Oral Suspension. If you have any questions or concerns about potential drug interactions or the use of this formulation, please reach out to us for further guidance and support.

Albendazole 20 mg/mL Oral Suspension is a liquid dosage form designed to deliver the active pharmaceutical ingredient, albendazole, in a homogeneous mixture. This formulation ensures that the medication is evenly dispersed throughout the liquid medium, allowing for accurate dosing and ease of administration, particularly for patients who may have difficulty swallowing tablets or capsules. The suspension is intended for oral use.

Albendazole is an anthelmintic medication, which means it is used to treat infections caused by parasitic worms. The mechanism of action of albendazole involves the inhibition of microtubule synthesis in the parasites. By binding to the beta-tubulin protein, albendazole disrupts the polymerization of tubulin into microtubules, which are essential components of the cellular structure and function in parasites. This disruption leads to impaired glucose uptake and depletion of the parasite's energy stores, ultimately resulting in the death of the parasite.

The oral suspension form of albendazole is particularly beneficial in ensuring that the medication is absorbed efficiently in the gastrointestinal tract. The liquid form allows for rapid dispersion and absorption, which can be crucial in achieving the desired therapeutic effect. Additionally, the suspension can be easily adjusted to provide the precise dosage required for different patients, making it a versatile option for treating a variety of parasitic infections. This flexibility is especially important in pediatric patients or those with specific dosing needs due to the severity of the infection or other underlying health conditions.

For prescribers, it is important to consider the specific parasitic infection being treated, as well as the patient's age, weight, and overall health status when determining the appropriate dosage of albendazole oral suspension. The formulation's ability to provide a consistent and reliable dose with each administration makes it a valuable tool in the management of parasitic infections. Patients should be advised to shake the bottle well before each use to ensure the medication is properly mixed, and to follow the prescribed dosing schedule to achieve optimal results.

If you have any questions about Albendazole 20 mg/mL Oral Suspension or its use in treating parasitic infections, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide you with the information and support you need to ensure appropriate treatment.

Albendazole 20 mg/mL Oral Suspension is primarily used for the treatment of parasitic worm infections, such as neurocysticercosis and hydatid disease. However, this formulation may have other potential uses beyond these primary indications. Albendazole, as an anthelmintic agent, works by inhibiting the polymerization of tubulin into microtubules, which is essential for the survival of parasitic worms. This mechanism of action suggests that albendazole could be effective against a broader range of parasitic infections, including those caused by other helminths and protozoa. For instance, it may be used off-label for the treatment of infections such as giardiasis, trichinosis, and certain types of filariasis, where its ability to disrupt the cellular structure of parasites can be beneficial.

In addition to its antiparasitic properties, albendazole has been studied for its potential anti-cancer effects. Research has indicated that albendazole may inhibit the growth of cancer cells by disrupting their microtubule formation, similar to its action on parasites. This has led to investigations into its use as an adjunct therapy in certain types of cancer, although more clinical trials are needed to establish its efficacy and safety in this context. Furthermore, albendazole's immunomodulatory effects have been explored in the treatment of autoimmune diseases and inflammatory conditions, where it may help modulate the immune response and reduce inflammation.

For prescribers considering albendazole for these alternative uses, it is important to weigh the potential benefits against the risks, as the safety profile of albendazole in these contexts may differ from its use in treating parasitic infections. Patients should be informed about the off-label nature of such treatments and monitored closely for any adverse effects. As with any medication, the decision to use albendazole for other purposes should be based on a thorough evaluation of the patient's condition, potential drug interactions, and individual response to treatment.

If you have any questions or need further information about the use of Albendazole 20 mg/mL Oral Suspension for these or other conditions, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to assist you with any inquiries you may have.